Trastuzumab deruxtecan
Daiichi Sankyo,AstraZeneca
 the adjugate drug trials offer an option for kras/her2 co-mutation. and some of the pharma companies are reserving spots on the trial. in patient fb groups, i've seen about 9 pts.
in first her2 trial only one of the 8 with co-mutation had response per dr chart.
volunteer #CRCSM librarian
#BRAF & #NRAS FB grps
Stage 4 CRC Support & Colon Cancer Stars
trials Stage 2/3 pts
https://t.co/48vU5493pH